Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rejuvesol Washed RBC in Sickle Cell Patients
NCT02731157Phase 4Completed
- Sponsor
- Duke University
- Start
- Dec 2016
- Primary completion
- Dec 2017
- Modality
- Injectable Hydrogels, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of rejuvesol in sickle cell disease (SCD) (2 arms), sponsored by Duke University. Primary endpoint: Average Percent Hemoglobin (HbA) Decrement Per Day at 6 months. Started Dec 2016; status: completed.
02
Drugs
rejuvesol
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NCT02731157.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02731157.